The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation
Open accessAbstract
A subset of patients with non-alcoholic fatty liver disease develop an inflammatory condition, termed non-alcoholic steatohepatitis (NASH). NASH is characterised by hepatocellular injury, innate immune cell-mediated inflammation and progressive liver fibrosis. The mechanisms whereby hepatic inflammation occurs in NASH remain incompletely understood, but appear to be linked to the proinflammatory microenvironment created by toxic lipid-induced hepatocyte injury, termed lipotoxicity. In this review, we discuss the signalling pathways induced by sublethal hepatocyte lipid overload that contribute to the pathogenesis of NASH. Furthermore, we will review the role of proinflammatory, proangiogenic and profibrotic hepatocyte-derived extracellular vesicles as disease biomarkers and pathogenic mediators during lipotoxicity. We also review the potential therapeutic strategies to block the feed-forward loop between sublethal hepatocyte injury and liver inflammation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Caloric overload, steatosis, oxidative stress, ER stress and hepatocyte ‘lipoapotosis’ represent first steps in cell-cell communication, triggering the fibroinflammatory cycle.13,23”
From Understanding the cellular interactome of non-alcoholic fatty liver disease (2022) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Extracellular vesicles: Exosomes, microvesicles, and friends
Raposo, G., & Stoorvogel, W. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201211138 · Cited by 8,099
Macrophage activation and polarization: nomenclature and experimental guidelines
Murray, P. J., Allen, J. E., Biswas, S. K., Fisher, E. A., Gilroy, D. W., Goerdt, S., Gordon, S., Hamilton, J. A., Ivashkiv, L. B., Lawrence, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.008 · Cited by 6,337
Nonalcoholic Fatty Liver Disease
Rinella, M. E. (2015) · JAMA · doi:10.1001/jama.2015.5370 · Cited by 2,320
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Programmed Cell Death in Animal Development and Disease
Fuchs, Y., & Steller, H. (2011) · Cell · doi:10.1016/j.cell.2011.10.033 · Cited by 1,915
Extracellular Vesicles: Unique Intercellular Delivery Vehicles
Maas, S. L. N., Breakefield, X. O., & Weaver, A. M. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2016.11.003 · Cited by 1,466
Liver Macrophages in Tissue Homeostasis and Disease
Krenkel, O., & Tacke, F. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.11 · Cited by 1,424
Liver inflammation and fibrosis
Koyama, Y., & Brenner, D. A. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88881 · Cited by 1,295
Research works printed but not linked: 1
- Lefebvre, 2013, Anti-fibrotic and anti-inflammatory activity of the dual CCR2 and CCR5 antagonist cenicriviroc in a mouse model of NASH, Hepatology, 58, 221
Cited by
Sorted by citations
Items 201–278 of 278
Navigating the Paradox of IL‐22: Friend or Foe in Hepatic Health?
Qin, J., Zhu, W., & Zhou, W. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16991 · Cited by 8
Lu, F., Chen, J., Yan, W., Ye, Z., Yu, J. H., Yao, G., Wu, Y., Zhang, J., & Yang, D. (2022) · Molecules · doi:10.3390/molecules27061790 · Cited by 7
Dysregulation of intercellular signaling by MOF deletion leads to liver injury
Lei, H., denDekker, A. D., Li, G., Zhang, Z., Liang, S., Schaller, M. A., Kunkel, S. L., Rui, L., Tao, K., & Dou, Y. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.016079 · Cited by 7
Zebrafish model of palmitic acid induced MAFLD recapitulates pathways conserved in mice and humans
Bhattacharya, D., Kaushal, S., Chakraborty, B., Raha, A., Dutta, T., Shekhar, H., Koner, A. L., Kumar, S., Ramachandran, R., Dhanjal, J. K., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-13154-5 · Cited by 9
Inflammation in Steatotic Liver Diseases: Pathogenesis and Therapeutic Targets
Qian, S., Wang, X., Chen, Y., Zai, Q., & He, Y. (2024) · Seminars in Liver Disease · doi:10.1055/a-2338-9261 · Cited by 6
Zheng, Y., Lu, Q., Cao, J., Han, G., Liu, Y., Liu, H., Jin, J., Zhang, Z., Yang, Y., Zhu, X., et al. (2024) · Aquaculture Reports · doi:10.1016/j.aqrep.2024.102266 · Cited by 7
Tseng, C.-M. L., Balic, K., Charlton, R. W., Margalit, M., Mansbach, H., & Savić, R. M. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3046 · Cited by 6
Cellular Interactions in the Human Fatty Liver
Sovaila, S., Silvia Sovaila, 2. P. R. S., Purcărea, A., Gheonea, D. I., Ionescu, S. O., & Ciurea, T. (2019) · Journal of Medicine and Life · doi:10.25122/jml-2019-1010 · Cited by 6
Arnold, J., Idalsoaga, F. J., Díaz, L. A., Cabrera, D., Francisco Barrera, M., Arab, J. P., & Arrese, M. A. (2024) · Current Hepatology Reports · doi:10.1007/s11901-023-00629-0 · Cited by 5
Homady, M. H. (2020) · Journal of Human Anatomy · doi:10.23880/jhua-16000147 · Cited by 5
Ge, Y., Deng, S., Zhang, X., Liu, H., Chen, Y., Liu, Y., Liu, S., Fu, H., Yang, Y., & Wu, Z. (2025) · Food & Function · doi:10.1039/d4fo01605j · Cited by 4
Centa, M., Thermidor, C., Fiel, M. I., & Alexandropoulos, K. (2023) · Clinical Immunology · doi:10.1016/j.clim.2023.109807 · Cited by 4
Ren, Y., Xiao, K., Lu, Y., Chen, W., Li, L., & Zhao, J. (2024) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgae103 · Cited by 4
Species differences of fatty liver diseases: comparisons between human and feline
Ling, L., Li, R., Xu, M., Zhou, J., Hu, M., Zhang, X., & Zhang, X.-J. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00014.2024 · Cited by 5
Hepatocellular Carcinoma: Known and Emerging Risk Factors
Sciancalepore, D., Zingaro, M. T., Luglio, C. V., Sabbà, C., & Napoli, N. (2018) · Journal of Cancer Therapy · doi:10.4236/jct.2018.95037 · Cited by 4
Ezz-Eldin, Y. M., Ewees, M. G., Khalaf, M. M., & Azouz, A. A. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177069 · Cited by 3
RIPK1 inhibition reduces biliary injury and fibrosis in primary sclerosing cholangitis
Soret, P., Steunou, V., Hedou, J. J., Tokgozoglu, J., Pistorio, V., Majdi, A., Darwane, N., Delaunay, J.-L., Benyahia, S., Dinard, L., et al. (2025) · Science Advances · doi:10.1126/sciadv.adz7907 · Cited by 3
Kwon, Y. S., Cho, Y. E., Kim, Y. S., Koh, M., & Hwang, S. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46030151 · Cited by 5
Extracellular Vesicles and Micro-RNAs in Liver Disease
Washington, A. M., & Kostallari, E. (2024) · Seminars in Liver Disease · doi:10.1055/a-2494-2233 · Cited by 4
Micheli, L., Pacini, A., Mannelli, L. D. C., Trallori, E., D’Ambrosio, R., Bianchini, C., Lampertico, P., & Ghelardini, C. (2020) · Nutrients · doi:10.3390/nu12061819 · Cited by 3
Metabolic Syndrome and Metabolic Dysfunction‐Associated Fatty Liver Disease
Koo, B. K., & Lim, S. K. (2022) · Wiley eBooks · doi:10.1002/9781119695257.ch13 · Cited by 3
Ezz-Eldin, Y. M., Azouz, A. A., Khalaf, M. M., & Ewees, M. G. (2026) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2026.2638333 · Cited by 2
The neurobiological regulatory mechanism of brain edema
Tian, M., Li, M., Zhang, C., Luo, Q., Wang, A. M., & Li, D. (2026) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2026.1777039 · Cited by 2
Wei, S., He, Y., Luo, C., & He, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1924392 · Cited by 4
Ultra structural Studies of Mouse Liver in Castrated Subjects Treated with Grape Juice
Homady, M. H. (2021) · International Journal of Clinical Case Reports and Reviews · doi:10.31579/2690-4861/082 · Cited by 2
Current NASH Pathogenesis and Diagnostic Techniques and Treatments
Dai, L. (2023) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v36i.6281 · Cited by 2
Yang, L.-C., Wang, C., Lee, D., Lin, W., Kuo, S., Juang, S., & Hsieh, M. (2024) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14532 · Cited by 2
Ma, X., Li, B., Liu, Y., & Guo, X. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1534200 · Cited by 2
Pagano, S., Somm, E., Jornayvaz, F. R., & Vuilleumier, N. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70092 · Cited by 2
R-spondin 2 suppresses hepatic steatosis via activation of AMPK-ACC signaling
Aithabathula, R. V., Singla, B., Kathuria, I., Pervaiz, N., Sharma, B. K., Samake, T. I., Ofosu-Boateng, M., Gebreyesus, L. H., Gyamfi, M. A., Sprague, C., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101551 · Cited by 2
CD4+ T cells promote fibrosis during metabolic dysfunction–associated steatohepatitis
Valenzuela-Pérez, L., Lee, H. S. K., Bayer, R. L., Manna, D. F., Mishra, S. K., Washington, A. M., Hassan, A., Sidahmed, M. M., Ssali, E., Dinç, E. J., et al. (2026) · Hepatology · doi:10.1097/hep.0000000000001772 · Cited by 4
Self-citationNew insights into the key role of extracellular vesicles in non-alcoholic fatty liver disease
Martínez, I. G., Alén, R., Rada, P., & Valverde, Á. M. (2022) · Anales de la Real Academia Nacional de Farmacia · doi:10.53519/analesranf.2022.88.03.02 · Cited by 2
Regulation of Iron Metabolism in NAFLD/NASH
Hamada, Y., & Hirano, E. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.107221 · Cited by 1
An Overview of Non-alcoholic Fatty Liver Diseases (NAFLD)
Kang, J., Kim, H.-J., Lim, S.-J., Lee, S., & Hwang, I. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1010672 · Cited by 1
Xu, L., Hu, S., Ye, Y., Xie, X., Zhou, P., Shen, H., & Zhao, X. (2025) · BMC Public Health · doi:10.1186/s12889-025-24948-7 · Cited by 1
Applications of Danio rerio as a model for studying NAFLD and NASH
Rafizadeh, M., Khazaei‐Poul, Y., Mohammadi, H., Khorramizadeh, M. R., Amoli, M. M., Larijani, B., & Ziai, S. A. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01780-9 · Cited by 1
Cao, L., Yang, W., Wang, C., Liu, C., Qi, W., Ren, R., Zhang, J., Yu, S., Li, Q., Cai, L., et al. (2026) · Hepatology · doi:10.1097/hep.0000000000001757 · Cited by 1
Wu, B., Wang, Z. G., Ji, P., Huang, X., Han, S., Mei, C., Ren, J., & Wu, M. (2026) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5c01198 · Cited by 1
Metabolic Dysfunction‐Associated Fatty Liver Disease: From Pathogenesis to Treatment
Cui, Z., Du, X., Amevor, F. K., Xia, Y., Yang, Y., & Liu, L. (2026) · MedComm · doi:10.1002/mco2.70832 · Cited by 1
Aithabathula, R. V., Collier, D. M., Singal, V., Rairao, S., Islam, R. A., Svetich, B., & Singla, B. (2026) · Life Sciences · doi:10.1016/j.lfs.2026.124687 · Cited by 1
Non-alcoholic Fatty Liver Disease - New Insight and Glance Into Disease Pathogenesis
Kang, S. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100998 · Cited by 1
RNA-seq analysis reveals transcriptome changes in livers from Efcab4b knockout mice
Cheng, C. W., Pedicini, L., Morales-Alcala, C. C., Deligianni, F., Smith, J., Murray, R. D., Todd, H. J., Forde, N., & McKeown, L. (2025) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2025.101944 · Cited by 1
Hanjani, N. A., & Vafa, M. R. (2018) · Journal of Gastroenterology and Hepatology Research · doi:10.17554/j.issn.2224-3992.2018.07.780 · Cited by 1
From fatty liver to nonalcoholic steatohepatitis with fibrosis
Muriel, P. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99764-5.00013-5 · Cited by 1
Non‐alcoholic Fatty Liver Disease
Rotman, Y., & Kapuria, D. (2020) · doi:10.1002/9781119436812.ch52 · Cited by 1
Lipotoxicity in Non-alcoholic Fatty Liver Disease: Mechanisms and Prevention in Experimental Models
Geng, Y. (2020) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.130260314 · Cited by 2
Cheng, C. W., Pedicini, L., Morales-Alcala, C. C., Deligianni, F., Forde, N., Smith, J., & McKeown, L. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.13.593681 · Cited by 1
Liver Inflammation: Short Uptodate
Mihăilă, M., Bontaş, E., & Patru, C. (2020) · Springer eBooks · doi:10.1007/978-3-030-24432-3_5
Villanueva, A. H. (2021) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.180853744
FLCN Gene Ablation Reduces Fibrosis and Inflammation in a Diet-Induced NASH ModelPreprint
Paquette, M., Yan, M., El–Houjeiri, L., Biondini, M., Ramírez-Reyes, J. M. J., Pacis, A., Jeong, H., Estall, J. L., Siegel, P. M., & Pause, A. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.10.291617
Li, M., & Yang, L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822003-0.00014-0
Nichtalkoholische Steatohepatitis (NASH) und alkoholische Steatohepatitis (ASH)
Roeb, E. (2021) · Drug Research · doi:10.1055/a-1606-5858
Treatment and Exploration of Non-Alcoholic Fatty Liver Disease in Traditional Chinese Medicine
(2022) · Journal of Contemporary Medical Practice · doi:10.53469/jcmp.2022.04(06).21
Nonalcoholic Fatty Liver in the Pathogenesis of Diabetes
Nogueira, C. A. V., & Leite, N. C. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_16
Purnomo, H. D., Kusuma, R. A., Sianturi, E., Haroen, R. F., Solichin, M. R., Nissa, C., Pramono, A., Mahati, E., & Noer, E. R. (2023) · Journal of Nutrition and Metabolism · doi:10.1155/2023/2313503
Wang, C.-J., Hu, Y., Bai, T., Li, ., Wang, H., Lv, X., Zhang, M., & Chang, F. (2024) · Medicine · doi:10.1097/md.0000000000038001
Cheng, C. W., Pedicini, L., Morales-Alcala, C. C., Deligianni, F., Smith, J., Forde, N., & McKeown, L. (2024) · Research Square · doi:10.21203/rs.3.rs-4425717/v1
Abnormalities of Carbohydrate Metabolism and the Liver
Brigham, D., & Sundaram, S. S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-11760-2.00074-4
Абатуров, А. Е., & Нікуліна, А. О. (2025) · Eastern Ukrainian Medical Journal · doi:10.21272/eumj.2025;13(3):606-621
Hwang, I., Lee, E. J., Park, H., Moon, D., & Kim, H.-S. (2021) · Figshare · doi:10.6084/m9.figshare.13532218
Mechanisms of Liver Regeneration
Kofler, A., Poelsler, L. H., Oberhuber, R., & Primavesi, F. (2026) · Springer eBooks · doi:10.1007/978-3-032-10997-2_1
Juan-García, C. A. S., Escamilla, R. I., Cruz-Romero, L., Hernández-Silva, C. D., Fernández-Quezada, D., la Cruz-Mosso, U. D., Pereira-Suárez, A. L., Haramati, J., Ramírez-López, I. G., Macías‐Barragán, J., et al. (2026) · World Journal of Hepatology · doi:10.4254/wjh.v18.i3.115111
Yang, M., Olaoba, O. T., Chinwo, S., LeVasseur, H. L., Zhou, B., Kimchi, E. T., Staveley-O’Carroll, K. F., & Li, G. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.v32.i14.117396
Homéostasie des céramides et hépatopathies métaboliques
Régnier, M. (2018) · theses.fr (ABES) · doi:10.70675/2fb92711z373cz4b27z8082z7aa3f8930e63
Influence du sexe dans la susceptibilité aux hépatopathies métaboliques
Smati, S. (2019) · theses.fr (ABES) · doi:10.70675/01997f55za990z41e6z96baz8221de2a6281
Impact de l'obésité sur la toxicologie des contaminants alimentaires : l'exemple de la Fumonisine B1
Dopavogui, L. (2022) · theses.fr (ABES) · doi:10.70675/8fcfcad7z134cz4df2zade9z155636aa8994
Morgante, C., Cammà, C., PETTA, S., Guarnotta, V., & Arnaldi, G. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.v32.i16.116142
Liang, J., Li, L., Chen, L., & Chen, W. (2026) · Dyes and Pigments · doi:10.1016/j.dyepig.2026.113805
Абатуров, А. Е., & Нікуліна, А. О. (2026) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.22.3.2026.1718
Chen, L., Wang, Y., Liu, S., Huo, G., Yang, Y., Xu, N., Wang, H., Zhao, H., Zhang, Z., Fu, R., et al. (2026) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/cjgh/7390933
Li, J.-Z., Zhang, L., Ye, L., Zou, W., Qi, Y., Wang, D., Cao, Y., Li, Q., Han, Y.-F., Wang, Y., et al. (2026) · Liver International · doi:10.1111/liv.70712
Orchestrated cell death pathways in cholangiopathies
Guicciardi, M. E., Pistorio, V., Soret, P., Steunou, V., Gores, G. J., & Gautheron, J. (2026) · Gut · doi:10.1136/gutjnl-2026-339264
Self-citationFoglia, B., Nurcis, J., Signorini, M., Novo, E., Bocca, C., Cannito, S., & Parola, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188213
Lipotoxicity in MAFLD/MASH: cellular mechanisms and targetable nodes
Tawai, J., Zhou, K., & Xiong, J. (2026) · Targetome · doi:10.48130/targetome-0026-0047
Metadata
- Authors
- Ibrahim, S. H., Hirsova, P., & Gores, G. J.
- Affiliations
- Mayo Clinic (US)
- Charles University (CZ)
- Corresponding author
- Gores, Gregory J
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2018-01-24
- Volume
- 67
- Issue
- 5
- Pages
- 963-972
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- PMC
- PMC5889737
- OpenAlex
- W2784619339
- Cited by
- 278
- References
- 89
- Citations by year
- 2026: 20 · 2025: 26 · 2024: 28 · 2023: 29 · 2022: 37 · 2021: 50 · 2020: 43 · 2019: 28 · 2018: 17
- FWCI
- 4.93
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Gut (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Mayo Clinic
- Gilead Sciences
- MH CZ–DRO
- National Institute of Diabetes and Digestive and Kidney Diseases
- North American Society of Pediatric Gastroenterology Hepatology and Nutrition Young Investigator Award/Nestle Nutrition Award
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, lipotoxicity, lipid overload, liver inflammation, liver fibrosis, disease biomarkers, treatment options
- MeSH terms
- Animals, Hepatitis, Humans, Lipids, Liver, Signal Transduction, Hepatocytes, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
